Scarica l'app Stockscreener
1.22
1.61%
-0.02
Dopo l'orario di chiusura:
1.21
-0.01
-0.82%
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Fate Therapeutics reports new employee inducement award under Nasdaq listing rule 5635(c)(4) - MarketScreener
Fate Therapeutics Announces New Employee Inducement Award - National Today
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Fate employee gets 7,260 stock units vesting over 4 years - Stock Titan
Street Watch: Is Fate Therapeutics Inc subject to activist investor interest2026 Rallies & Weekly Breakout Watchlists - baoquankhu1.vn
FATE Should I Buy - Intellectia AI
Fate Therapeutics Inc Stock: Pioneering iPSC Cell Therapies Amid Biotech Volatility - AD HOC NEWS
Fate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving AverageHere's What Happened - marketbeat.com
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
Scalable Biotech Manufacturing Unlocks a $14B Market - Sahm
Vanguard (FATE) reports 0 shares after internal realignment - Stock Titan
Mizuho reiterates Fate Therapeutics stock rating on trial progress By Investing.com - ca.investing.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages - marketbeat.com
Take Profit: Will Fate Therapeutics Inc outperform small cap indexes2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Fate Therapeutics Inc stock faces analyst caution amid biotech pipeline scrutiny - AD HOC NEWS
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed - MarketScreener
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 14.1% in February - MarketBeat
Big Picture: Can Fate Therapeutics Inc beat the S P 5002026 Intraday Action & Trade Opportunity Analysis Reports - baoquankhu1.vn
FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference - MarketBeat
Performance Recap: Can Fate Therapeutics Inc ride the EV waveProduct Launch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Lessons From Bringing A Novel T Cell Class For Autoimmune Diseases Into The Clinic - Clinical Leader
Valuation Update: Can Fate Therapeutics Inc lead its sector in growthWeekly Trading Summary & AI Powered Market Entry Strategies - baoquankhu1.vn
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates - MSN
Fate Therapeutics at Leerink Global Healthcare Conference: Strategic Shift in Focus - Investing.com Canada
FATE: FT819 shows promising efficacy and safety in lupus nephritis, with pivotal trials set for later this year - TradingView
Dividend Watch: Can Fate Therapeutics Inc. ride the EV waveCEO Change & Risk Controlled Daily Trade Plans - baoquankhu1.vn
CEO Change: Can Fate Therapeutics Inc keep up with sector leaders2026 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
Fate Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Risk Analysis: Can Fate Therapeutics Inc lead its sector in growthJuly 2025 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Fed Meeting: Can Fate Therapeutics Inc beat the S P 5002025 Technical Patterns & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Bull Bear: Can Fate Therapeutics Inc lead its sector in growthFed Meeting & Fast Entry and Exit Trade Plans - baoquankhu1.vn
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
New Fate Therapeutics hires get 50,700 stock units over 4 years - Stock Titan
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewswire
FATE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Growth Value: Is Fate Therapeutics Inc subject to activist investor interestQuarterly Market Summary & High Return Trade Opportunity Guides - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail
Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations - MarketBeat
Fate Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Baird reiterates Fate Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Fate Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Fate Therapeutics: Fourth Quarter Earnings Overview - bitget.com
Biotechnology company Fate Therapeutics Inc announced that its current cash reserves are sufficient to sustain company operations until the end of 2027. - Bitget
FATE THERAPEUTICS INC SEC 10-K Report - TradingView
Fate Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - The Manila Times
Fate Therapeutics reports lower Q4 collaboration revenue - TradingView
Form 10-K FATE THERAPEUTICS INC For: Dec 31 - StreetInsider
Earnings Summary: Fate Therapeutics Q4 - Benzinga
Fate Therapeutics (NASDAQ: FATE) cuts 2025 expenses, extends cash runway - Stock Titan
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World
Bond Watch: What are AFBIs technical support levels2025 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
Aug Patterns: Will Fate Therapeutics Inc outperform small cap indexes2025 Price Action Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
Fate Therapeutics (FATE) to Release Earnings on Wednesday - MarketBeat
Critical Review: Fate Therapeutics (NASDAQ:FATE) vs. TuHURA Biosciences (NASDAQ:HURA) - Defense World
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):